Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Raf kinase inhibitor protein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Raf kinase inhibitor protein. Displaying page 1 of 1.
    EudraCT Number: 2017-000456-26 Sponsor Protocol Number: Tumorspheres_Colrec Start Date*: 2017-07-10
    Sponsor Name:Vejle Hospital
    Full Title: Predictive value of in-vitro testing anti-cancer therapy sensitivity on tumorspheres from patients with metastatic colorectal cancer
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003300-12 Sponsor Protocol Number: LOKON003 Start Date*: 2019-12-20
    Sponsor Name:Lokon Pharma AB
    Full Title: A Phase I/II Trial Investigating LOAd703 in Combination with Atezolizumab in Malignant Melanoma
    Medical condition: Malignant melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000185-22 Sponsor Protocol Number: 20110265 Start Date*: 2014-12-03
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma
    Medical condition: Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Prematurely Ended) BE (Completed) DE (Prematurely Ended) AT (Prematurely Ended) GR (Completed) IT (Prematurely Ended) FI (Prematurely Ended) CZ (Completed) PT (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003296-19 Sponsor Protocol Number: AFM24-101 Start Date*: 2020-03-27
    Sponsor Name:Affimed GmbH
    Full Title: A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers
    Medical condition: Advanced solid malignancies in patients whose disease has progressed after treatment with previous anticancer therapies.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004842-92 Sponsor Protocol Number: SECOMBIT Start Date*: 2016-06-30
    Sponsor Name:FONDAZIONE MELANOMA ONLUS
    Full Title: A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit...
    Medical condition: Metastatic melanoma and BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing) DE (Completed) GR (Completed) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) SE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005110-34 Sponsor Protocol Number: ICT01-102 Start Date*: 2022-02-08
    Sponsor Name:ImCheck Therapeutics, Inc.
    Full Title: A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advance...
    Medical condition: Relapsed/refractory patients with advanced solid tumors : metastatic colorectal cancer (CRC) or metastatic ovarian cancer or metastatic castration-resistant prostate cancer (mCRPC) or metastatic pa...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004323-20 Sponsor Protocol Number: BNT211-01 Start Date*: 2020-06-30
    Sponsor Name:BioNTech Cell & Gene Therapies GmbH
    Full Title: Phase 1/2a, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-...
    Medical condition: CLDN6-positive relapsed or refractory advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043302 Testicular cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046766 Uterine cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007460 Carcinoma of unknown primary LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 15:23:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA